Bausch + Lomb (BLCO) Q1 2026 earnings review
Profitability Inflection and Raised Guidance Override Lingering Macro Risks
Bausch + Lomb delivered a remarkably clean Q1 2026, demonstrating that the structural margin improvements promised in FY25 are flowing to the bottom line. While revenue grew a solid 9% YoY to $1.24B, the real story is the operational leverage: Adjusted EBITDA Excluding Acquired IPR&D surged 59% YoY to $200M. Operating cash flow and GAAP operating income both flipped to positive territory. The Pharmaceuticals segment continues to carry the growth narrative with double-digit expansion, allowing management to confidently raise FY26 revenue and profit guidance despite explicitly excluding potential tariff impacts from their models.
🐂 Bull Case
MIEBO (+33%) and XIIDRA (+30%) are driving 14% growth in the Pharmaceuticals segment. As these shift from launch-phase investment to growth-phase execution, they are aggressively pulling up company-wide margins.
SG&A expenses actually fell YoY ($544M vs $563M) despite 9% top-line growth. Management explicitly cited 'broad AI adoption' helping drive these operational efficiencies.
🐻 Bear Case
Surgical constant currency growth decelerated to just 1%. Given management highlighted growth in 'premium IOLs', this implies the base monofocal business is still suffering the hangover from the 2025 enVista recall.
Guidance explicitly excludes any changes in tariff policy. With global supply chain dependencies and previous admissions of a potential ~120 bps margin headwind from tariffs, the guidance carries asterisks.
⚖️ Verdict: 🟢
Bullish. The trajectory is undeniable: top-line growth is stable, but margin expansion is accelerating rapidly. The turnaround from a $83M operating loss in 25Q1 to a $33M profit in 26Q1 shows the 'Vision 27' margin expansion program is executing ahead of schedule.
Key Themes
Pharmaceuticals Segment Accelerating on Dry Eye Dominance
The Pharmaceuticals segment grew 14% YoY (12% constant currency) to $305M, establishing itself as the company's growth engine. This was spearheaded by massive gains in the dry eye portfolio: MIEBO surged 33% and XIIDRA jumped 30%. This confirms management's strategy of absorbing upfront gross-to-net hits to secure market access for XIIDRA is paying off in subsequent volume and profit.
AI-Driven Operational Efficiencies Reshaping the P&L
For the first time, management explicitly credited 'broad AI adoption' for driving operational efficiencies. This is clearly visible in the P&L: Selling, General, and Administrative (SG&A) expenses dropped from $563M in 25Q1 to $544M in 26Q1. Achieving absolute cost reduction while growing revenue 9% is a textbook definition of operational leverage.
Consumer Product Launches Refreshing Vision Care
Vision Care posted a solid 8% YoY growth ($711M). This segment is getting a much-needed innovation injection with the nationwide rollouts of PreserVision AREDS3 and Blink Triple Care Preservative Free. These launches are crucial for reviving the historically flat eye vitamin category.
Surgical Base Business Stagnating
A concerning data point contradicts the overall positive narrative: Surgical segment growth crashed to just 1% on a constant currency basis (7% reported, aided by FX). While the PR highlights 'growth in premium IOLs', the arithmetic implies that the core, lower-margin monofocal business remains weak, potentially still struggling to win back contracts lost during the 2025 enVista recall.
Tariff Risks Excluded from Guidance
Management noted that the updated 2026 guidance 'does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.' In 2025, management estimated tariffs could be up to a 120 bps headwind to EBITDA margins. By excluding this from current models, the raised guidance carries external policy risk.
BHC Separation Overhang Persists
The forward-looking statements continue to heavily caveat the pending separation from Bausch Health Companies (BHC). The limited public float and structural dependency on BHC reaching specific debt leverage ratios remain an active headwind for valuation multiple expansion, entirely outside Bausch + Lomb's operational control.
Other KPIs
Reversing. A massive $57M positive swing from the $25M cash burn in the prior year period. Q1 is historically the weakest seasonal cash flow quarter for the company due to working capital dynamics and rebate payments. Posting positive cash flow here sets a strong baseline for robust free cash flow generation for the remainder of FY26.
Reversing. Flipped from an $83M operating loss in 25Q1. This $116M favorable swing was achieved through a combination of higher gross profits (revenue scale) and strict discipline on operating expenses (SG&A down YoY).
Guidance
Accelerating. Raised from the prior outlook of $5.375B - $5.475B. The midpoint ($5.47B) implies roughly 7.2% YoY growth compared to FY25 ($5.10B). The raise is fueled by $20M in additional expected FX tailwinds and better-than-expected base business momentum.
Accelerating. Raised from the prior $1.000B - $1.050B range. The midpoint of $1.035B implies a 16% YoY growth rate versus FY25 ($891M), significantly outpacing the ~7% implied revenue growth. This confirms the operating leverage thesis that is central to the bull case.
Stable to Accelerating. Nudged up from the prior 5.0% - 7.0% range. This shows that the guidance raise is not merely an FX accounting adjustment, but reflects genuine fundamental demand upgrades across the product portfolio.
Key Questions
Surgical Base Business Health
Surgical constant currency growth decelerated to 1% in Q1. While premium IOLs are growing, what is the specific trajectory of the base monofocal business? Are you still fighting 'hangover' effects from contracts lost during last year's enVista recall?
AI and Cost Structure Sustainability
You cited 'broad AI adoption' as a driver for operational efficiencies, which helped SG&A fall YoY. Is this an absolute structural step-down in the cost base, or should we expect SG&A growth to resume normalized pacing in the back half of the year?
Tariff Contingency Triggers
Your FY26 guidance explicitly excludes tariff impacts. What are the specific triggers or thresholds in trade policy that would require you to revise this guidance, and how quickly can your global manufacturing footprint pivot to mitigate those hits?
BHC Separation Update
Given the strong cash flow and EBITDA trajectory you're demonstrating independently, is there any update on BHC's progress toward the debt leverage ratios required to finalize the corporate separation?